Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Selling, General & Admin	5.14	3.08	3.48	7.42	7.12
Research & Development	3.63	1.41	6.46	7.45	5.2
Operating Expenses	8.77	4.5	9.94	14.87	12.32
Operating Income	-8.77	-4.5	-9.94	-14.87	-12.32
Interest Expense	-0.01	-0.02	-0.01	-0.01	-0.05
Interest & Investment Income	0	-	-	-	-
EBT Excluding Unusual Items	-8.77	-4.51	-9.95	-14.88	-12.37
Other Unusual Items	-	-	-	-	0
Pretax Income	-8.77	-4.51	-9.95	-14.88	-12.36
Net Income	-8.77	-4.51	-9.95	-14.88	-12.36
Preferred Dividends & Other Adjustments	-	0.59	-	-	-
Net Income to Common	-8.77	-5.11	-9.95	-14.88	-12.36
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	3	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0
Shares Change	640.27%	499.67%	4.07%	9.45%	22.64%
EPS (Basic)	-2.63	-11.32	-132.33	-205.97	-187.31
EPS (Diluted)	-2.63	-11.32	-132.33	-205.97	-187.31
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Free Cash Flow	-8.07	-6.87	-8.42	-8.92	-6.72
Free Cash Flow Per Share	-2.42	-15.24	-111.97	-123.53	-101.83
EBITDA	-8.66	-4.45	-9.89	-14.85	-12.32
D&A For EBITDA	0.11	0.05	0.05	0.02	0
EBIT	-8.77	-4.5	-9.94	-14.87	-12.32

SEC Filings: 10-K · 10-Q